Organization and transmitter specificity of medullary neurons activated by sustained hypertension: implications for understanding baroreceptor reflex circuitry.
In situ expression of c-fos observed in response to phenylephrine (PE)-induced hypertension provided a basis for characterizing the organization and neurotransmitter specificity of neurons at nodal points of medullary baroreflex circuitry. Sustained hypertension induced by a moderate dose of PE provoked patterns of c-fos mRNA and protein expression that conformed in the nucleus of the solitary tract (NTS) to the termination patterns of primary baroreceptor afferents and in the caudal ventrolateral medulla (CVLM) to a physiologically defined depressor region. A majority of barosensitive CVLM neurons concurrently displayed markers for the GABAergic phenotype; few were glycinergic. Phenylephrine-sensitive GABAergic neurons that were retrogradely labeled after tracer deposits in pressor sites of the rostral ventrolateral medulla (RVLM) occupied a zone extending approximately 1.4 mm rostrally from the level of the calamus scriptorius, intermingled partly with catecholaminergic neurons of the A1 and C1 cell groups. By contrast, barosensitive neurons of the NTS were found to be phenotypically complex, with very few projecting directly to the RVLM. Extensive colocalization of PE-induced Fos-IR and markers for the nitric oxide phenotype were seen in a circumscribed, rostral, portion of the baroreceptor afferent zone of the NTS, whereas only a small proportion of PE-sensitive neurons in the NTS were found to be GABAergic. PE treatment parameters have been identified that provide a basis for defining and characterizing populations of neurons at the first station in the central processing of primary baroreceptor input and at a key inhibitory relay in the CVLM.
Chan
R K
RK
Laboratory of Neuronal Structure and Function, The Salk Institute, La Jolla, California 92037, USA.
Sawchenko
P E
PE
D000818:Animals; D017704:Baroreflex / Q000502:physiology*; D015415:Biomarkers; D002319:Cardiovascular System / Q000187:drug effects / Q000294:innervation; D002395:Catecholamines / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D005998:Glycine / Q000032:analysis; D006973:Hypertension / Q000139:chemically induced / Q000503:physiopathology*; D008297:Male; D009046:Motor Neurons / Q000737:chemistry / Q000378:metabolism; D009252:NADPH Dehydrogenase / Q000032:analysis / Q000378:metabolism; D009433:Neural Inhibition / Q000502:physiology; D009475:Neurons, Afferent / Q000737:chemistry / Q000201:enzymology*; D018377:Neurotransmitter Agents / Q000096:biosynthesis / Q000378:metabolism; D009569:Nitric Oxide / Q000032:analysis / Q000378:metabolism; D019001:Nitric Oxide Synthase / Q000032:analysis / Q000378:metabolism; D010641:Phenotype; D010656:Phenylephrine; D016760:Proto-Oncogene Proteins c-fos / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism; D012333:RNA, Messenger / Q000032:analysis; D051381:Rats; D017207:Rats, Sprague-Dawley; D017552:Solitary Nucleus / Q000166:cytology*; D013566:Sympathomimetics; D014446:Tyrosine 3-Monooxygenase / Q000032:analysis / Q000378:metabolism; D014630:Vagus Nerve / Q000166:cytology; D005680:gamma-Aminobutyric Acid / Q000032:analysis
D015415:Biomarkers; D002395:Catecholamines; D018377:Neurotransmitter Agents; D016760:Proto-Oncogene Proteins c-fos; D012333:RNA, Messenger; D013566:Sympathomimetics; D010656:Phenylephrine; D009569:Nitric Oxide; D005680:gamma-Aminobutyric Acid; D019001:Nitric Oxide Synthase; D014446:Tyrosine 3-Monooxygenase; D009252:NADPH Dehydrogenase; D005998:Glycine